To evaluate this hypothesis, our team recently investigated the association of the BRCA2 p.K3326* mutation with breast cancer risk in the context of an ALDH2 intronic variant (rs10744777) among 11,873 breast cancer patients and 7,615 ethnically matched controls from Poland [30]. This evidence concerns the gene BRCA2 and breast cancer.